WUXI XDC Aktie

 

WUXI XDC (02268.HK) reported 2H25 results that were largely in line with its earlier alert, with revenue increasing by 35.9% YoY, and net profit ring by 26.4% to RMB735 million, Goldman Sachs published a research report saying.The management's 2026 guidance was in line with expectations. At a constant exchange rate, based on......

WUXI XDC (02268.HK) opened 3.54% higher today, and peaked at $54.2. It last printed at $53.35, advancing 5.02%, with a trading volume of 292,500 shares, involving $15.6051 million.The Group announced its 2025 annual results yesterday, reporting a revenue of RMB5.944 billion, up 46.7% YoY. Gross profit amounted to RMB2.139 billio......

Revenue increased by 46.7% YoY to RMB 5,944 million Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6......

Morgan Stanley issued a research report believing that the share price of WUXI XDC (02268.HK) will absolutely rise in the next 30 days, mainly due to the recent decline in the trading price of the stock, making its short-term valuation more attractive. WUXI XDC announced a substantial out-licensing agreement involving its payloa......

SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic......

WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) on WuXi XDC's proprietary......

WUXI BIO (02269.HK) and WUXI XDC (02268.HK) stumbled by approx. 7% and 8% on Thursday (26th), while Hong Kong-listed CRO/CDMO companies lost by about 2-to 9% overall, CLSA released a research report saying. The broker believed that this decline is not driven by fundamentals but is more likely largely positioning and capital flow......

As WUXI XDC (02268.HK) recently disclosed preliminary results for 2025, with a decline in operating margins, Morgan Stanley trimmed its earnings forecast for 2026-30 by 1-2%, and the target price was adjusted down by 2%, from HKD88 to HKD86, the broker said in a research report. Besides, the broker predicted that the adjusted ne......

Nomura lowered its 2025 revenue/ profit forecasts for WUXI XDC (02268.HK) by 4.5%/ 8.7% each to reflect the actual data released by the Company last month.Meanwhile, the broker anticipated revenue from commercial stage projects to be RMB181 million, and the acquisition of BIODLINK-B (01875.HK) to contribute a revenue of RMB150 m......

WUXI XDC (02268.HK) has issued a positive profit forecast for 2025, in which it predicted its revenue to have increased by more than 45% YoY on rapid order growth and the commissioning of Wuxi DP3, according to BOCOMI's research report.The company also estimated its gross profit to have surged by more than 70% on continuous ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

WUXI XDC (02268.HK) has issued a positive profit alert projecting its 2025 revenue/ net profit to have grown by at least 45%/ over 38% YoY, according to CMBI's research report. The adjusted net profit, meanwhile, is expected to have risen by over 45%. It could even reach over 65% if excluding foreign exchange effects.CMBI ha......

WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead...

BIODLINK-B (01875.HK) received a takeover bid from WUXI XDC (02268.HK) at a 60% premium. After resuming trading this morning (15th), BIODLINK-B's stock price once peaked at HKD3.97. It last traded at HKD3.93, up 57.2%, with a volume of 2.8 million shares and a turnover of HKD11.0256 million.BIODLINK-B, WUXI BIO (02269.HK), a......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

UBS has published a research report reiterating a Buy rating on WUXI XDC (02268.HK) for its leading position in the bioconjugate CRDMO platform, continuous capacity expansion, and controllable geopolitical risks. The broker's target price was HKD89.5.In 2025, WUXI BIO (02269.HK), WUXI XDC's parent company, added a total ......

Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work...

Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 WUXI XDC(02268.HK) | Buy | 74 SINO BIOPHARM(01177.HK) | Buy | 9.4 ~AAStocks Financial NewsWeb Site: www.aastocks.com...

According to JPMorgan's research report, while the Chinese healthcare sector retreated from its highs in September and October due to the results of the national medical insurance drug list price negotiations and subsequent profit-taking, the broker believes the industry's fundamentals remain unchanged, and the recent we......